Aktive Positionen von Jean-Pierre Julien
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
ImStar Therapeutics, Inc.
 ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | Direktor/Vorstandsmitglied | 01.01.2012 | - |
| Technik-/Wissenschafts-/F&E-Leiter | 01.01.2012 | - | |
| Gründer | 01.01.2012 | - |
Karriereverlauf von Jean-Pierre Julien
Statistik
International
| Kanada | 2 |
Operativ
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sektoral
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
ImStar Therapeutics, Inc.
ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | Health Technology |
- Börse
- Insiders
- Jean-Pierre Julien
- Erfahrung
